|drug2566||Nitrogen gas Wiki||0.71|
|drug910||Chloroquine or Hydroxychloroquine Wiki||0.58|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The primary objective of this study is to provide expanded access of S-nitrosylation therapy for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
Description: Total hospitalization days: Hospitalization data will be collected from the EMR on Day 30. Treatment will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.Measure: Length of Hospital Stay Time: 30 days
Description: Total ventilator days:Ventilator Days will be recorded for each day through Day 30. The number of days on the ventilator will be counted and then used to calculate the number of ventilator free days. Days that subjects are weaning off and on the ventilator will be counted as days on the ventilator.Measure: Number of Ventilator Days Time: 30 days
Description: Total days in ICU: Intensive Care Unit Days will be recorded for each day through Day 30. Days will be counted in 24-hour periods, any partial days will be counted as a whole day. The level of ICU care needed will be recorded, based on clear definitions and specific clinical criteria in the covid-19 critical care procedure manual, as follows: Level 1 - Mechanical ventilation and intensivist support. Patient is stable on lung protective equipment. Level 2 - Advanced mechanical ventilation (capability to prone) and 24 hour intensivist support. Patient is hypoxic. Patient is stabilized on escalated ventilator settings (high PEEP, prone, etc.) Level 3 - Advanced oxygenation/ventilation strategies, including ECMO and 24 intensivist support. Patient is severely hypoxic (ARDS), code status is discussed, palliative consult is discussed, RESP-ECMO parameters, and patient is ECMO candidate.Measure: Length of Intensive Care Time: 30 days
Description: 30-day all-cause mortalityMeasure: All-Cause Mortality Time: 30 days
Description: Adverse events related to SNO therapy.Measure: Treatment Emergent Adverse Events Time: 30 days
Description: Number of days required to see a greater than 2 point improvement on a 7-point respiratory status assessment ordinal scale. 7-Point Respiratory Severity Scale Range: 1-7 Higher values = worse Not receiving oxygen supplementation; AND room air oxygen saturation ≥ 95% Supplemental oxygen ≤ 2 liters/min; OR room air oxygen saturation ≤ 94% Supplemental nasal oxygen >2 and <= 5 liters/min Supplemental nasal oxygen >5 liters/min HFNC or NIV with FiO2 > 50% Intubation or ECMO DeathMeasure: Time to Respiratory Status Improvement Time: 30 days
Description: Proportion of patients in each stage at maximum severity on the 7-point clinical status assessment ordinal scale. Clinical status will be assessed using a 7-point ordinal scale as follows: Death Hospitalized, on invasive mechanical ventilation or ECMO Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, requiring low flow supplemental oxygen Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care Not hospitalizedMeasure: Clinical Status Time: 30 days
Description: Respiratory clinical status assessed by a 7-point respiratory status ordinal scale that captures oxygen requirement, ventilator support or death. 7-Point Respiratory Severity Scale Range: 1-7 Higher values = worse Not receiving oxygen supplementation; AND room air oxygen saturation ≥ 95% Supplemental oxygen ≤ 2 liters/min; OR room air oxygen saturation ≤ 94% Supplemental nasal oxygen >2 and <= 5 liters/min Supplemental nasal oxygen >5 liters/min HFNC or NIV with FiO2 > 50% Intubation or ECMO DeathMeasure: Respiratory Clinical Status Time: 30 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports